전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved188 programs
CGTLimited DatastaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy-vMCO-010 (Gene Therapy-vMCO-010)

Stargardt Disease · Stargardt Disease

#StargardtDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleCelgenePhase 3

Gene-modified (GM, Gene-modified, Gene-modified (GM) T cell therapy)

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleShuhong YiPhase 2

atezolizumab (Tecentriq, Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab)

Recurrent Liver Cancer After Liver Transplantation · Recurrent Liver Cancer After Liver Trans

#RecurrentLiverCancerAfterLiverTr#Antibody#Phase2#monoclonal-antibody#Shuhong
Trials 1Status Active
CGTLimited DatastaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleHunan Zhaotai Yongren Medical I…Phase 2

ITNK cell therapy (ITNK cell therapy)

Anti-cancer Cell Immunotherapy; T Cell and NK Cell · Anti-cancer Cell Immunotherapy

#Anti-cancerCellImmunotherapy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
CGTLimited DatastaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Ivonescimab Combined With Chemotherapy (Ivonescimab Combined With Chemotherapy)

Relapsed or Metastatic Thymic Cancer; First-line Treatment · Relapsed or Metastatic Thymic Cancer

#RelapsedorMetastaticThymicCancer#Antibody#Phase2#monoclonal-antibody#First-lineTreatment+1
Trials 1Status Recruiting
CGTLimited DatastaleWest China HospitalPhase 1

JWK010 gene therapy (JWK010 gene therapy)

Oculocutaneous Albinism (OCA) · Oculocutaneous Albinism (OCA)

#OculocutaneousAlbinismOCA#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleTongji HospitalPreclinical

Mab Therapy (Mab Therapy)

NMO Spectrum Disorder · NMO Spectrum Disorder

#NMOSpectrumDisorder#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
CGTAAVLimited DatastaleElisigen, Inc.Phase 2

NG101 AAV gene therapy (NG101 AAV gene therapy)

Age-Related Macular Degeneration · Age-Related Macular Degeneration

#Age-RelatedMacularDegeneration#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Neoadjuvant chemotherapy combined with Toripalimab (Neoadjuvant chemotherapy combined with Toripalimab)

TNBC, Triple Negative Breast Cancer · TNBC, Triple Negative Breast Cancer

#TNBCTripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#TNBC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#monoclonal-antibody#OvarianCancerStageIV+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab)

HR Positive/HER2 Low Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HRPositive+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

7 / 10 pages

← PreviousNext →